Q98408231

Summary

Q98408231 is a report^[1].

Key Facts

• Q98408231's instance of is recorded as report^[2].
• Q98408231's part of the series is recorded as reports of the 2016/17 legislative session of the Riksdag^[3].
• Q98408231's language of work or name is recorded as Swedish^[4].
• Q98408231's publication date is recorded as +2017-02-27T00:00:00Z^[5].
• Q98408231's significant event is recorded as debate^[6].
• Q98408231's main subject is recorded as medication^[7].
• Q98408231's work available at URL is recorded as http://data.riksdagen.se/dokument/H401SoU12^[8].
• Q98408231's work available at URL is recorded as http://data.riksdagen.se/dokumentstatus/H401SoU12^[9].
• Q98408231's work available at URL is recorded as http://data.riksdagen.se/fil/CE757FE1-1C8B-4E8E-86E5-60D97D1DA7FB^[10].
• Q98408231's applies to jurisdiction is recorded as Sweden^[11].
• Q98408231's legal citation of this text is recorded as bet. 2016/17:SoU12^[12].
• Q98408231's title is recorded as Riksrevisionens rapport om säkra och effektiva läkemedel^[13].
• Q98408231's has immediate cause is recorded as Q97761054^[14].
• Q98408231's has immediate cause is recorded as Q97761062^[15].
• Q98408231's maintained by WikiProject is recorded as Project Riksdagen's documents^[16].
• Q98408231's copyright status is recorded as public domain^[17].
• Q98408231's legislative committee is recorded as Committee on Health and Welfare^[18].
• Q98408231's Swedish Riksdag document ID is recorded as H401SoU12^[19].